Precigen doses first patients with UltraCAR-T cells

By The Science Advisory Board staff writers

November 17, 2020 -- Precigen said that the first patients in two phase I clinical trials have been treated with UltraCAR-T cells manufactured by its UltraPorator system.

In an ongoing phase I study conducted in collaboration with the University of Washington/Fred Hutchinson Cancer Research Center, PRGN-3005 UltraCAR-T cells were inserted in the intraperitoneal arm of patients as part of the study for advanced ovarian cancer patients, Precigen said.

Meanwhile, PRGN-3006 UltraCAR-T cells have also been used in dosing of patients with relapsed or refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) as part of an ongoing phase I/IB study that's being conducted in collaboration with the Moffitt Cancer Center.

Precigen nabs FDA nod for manufacturing UltraCAR-T therapies
Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology...
Precigen begins clinical trial for HPV-positive tumors
Precigen has dosed the first patients with Prgn-2009, an off-the-shelf investigational immunotherapy candidate, in a phase I/II clinical trial for the...
Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune...
Precigen touts heart failure multigenic therapy results
Precigen is highlighting clinical results from a phase I trial conducted by its subsidiary Precigen Triple-Gene that show that its multigenic investigational...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter